Ovarian tumor antigens: a new potential for therapy.
A murine tumor-associated alpha-globulin was identified by immunofluorescence, cytotoxicity, and immunoelectrophoresis. The antiserum resulting from heterologous immunization with the segregated antigen was tolerated in multiple injections and was therapeutic; host cell participation by macrophages and lymphocytes led to the therapeutic result. Investigation of human ovarian carcinoma demonstrated an alpha-globulin which shares antigenic specificity with other tumor-associated antigens. The successful scanning of a tumor mass with a heterologous antibody directed against a tumor-associated antigen demonstrated the feasibility of applying these techniques to clinical cancer.
D000818:Animals; D000951:Antigens, Neoplasm / Q000008:administration & dosage*; D003601:Cytotoxicity Tests, Immunologic; D005260:Female; D007106:Immune Sera / Q000494:pharmacology; D007116:Immunization, Passive; D007167:Immunotherapy; D037102:Lectins / Q000494:pharmacology; D008213:Lymphocyte Activation; D051379:Mice; D008809:Mice, Inbred C3H; D009374:Neoplasms, Experimental; D010051:Ovarian Neoplasms / Q000276:immunology / Q000628:therapy*
D000951:Antigens, Neoplasm; D007106:Immune Sera; D037102:Lectins